Clinical trial
Cetuximab in Treating Patients With Persistent or Recurrent Cervical Cancer
NCT00499031 · Gynecologic Oncology Group, Other · Completed
Key facts
| NCT number | NCT00499031 |
|---|---|
| Title | Cetuximab in Treating Patients With Persistent or Recurrent Cervical Cancer |
| Official title | A Phase II Evaluation of Cetuximab (Erbitux®, C225, NSC# 714692) in the Treatment of Persistent or Recurrent Squamous or Non-Squamous Cell Carcinoma of the Cervix |
| Lead sponsor | Gynecologic Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cervical Squamous Cell Carcinoma, Recurrent Cervical Carcinoma |
| Intervention type | Biological |
| Interventions | Cetuximab |
| Enrollment | 38 |
| Start date | Jun 1, 2007 |
| Primary completion | Jan 1, 2012 |
| First posted | Jul 11, 2007 |
| Last update posted | Jan 13, 2015 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: